Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero persistence and booster extension study in adolescents and young adults
2017-000093-11Phase 3
- Sponsor
- GSK
- Start
- Feb 2017
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Solicited local and systemic adverse events.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2017-000093-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000093-11.